Modified apple polysaccharide prevents against tumorigenesis in a mouse model of colitis-associated colon cancer: Role of galectin-3 and apoptosis in cancer prevention

European Journal of Nutrition

Volumn 51, Issue 1, 2012, Pages 107-117

  Li, Yuhua ^a,c   Liu, Li ^a   Niu, Yinbo ^b   Feng, Juan ^a   Sun, Yang ^a   Kong, Xianghe ^b   Chen, Yongchun ^c   Chen, Xiaoyan ^c   Gan, Hongquan ^a   Cao, Shousong ^d   Mei, Qibing ^a,b  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b NORTHWESTERN POLYTECHNICAL UNIVERSITY   (China)

^c No 422 Hospital of PLA   (China)

^d ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Apoptosis; Cancer prevention; Colitis associated colon cancer; Galectin 3; Modified apple polysaccharide

Indexed keywords

1,2 DIMETHYLHYDRAZINE; CASPASE 3; GALACTOSE; GALACTURONIC ACID; GALECTIN 3; POLYSACCHARIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; APPLE; ARTICLE; CANCER PREVENTION; COLITIS; COLON CANCER; COLON CARCINOGENESIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG CYTOTOXICITY; DRUG MECHANISM; DRUG PROTEIN BINDING; ENZYME ACTIVITY; EPITHELIUM CELL; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NICK END LABELING; NONHUMAN; PROTEIN FUNCTION; WESTERN BLOTTING;

ANIMALS; ANTICARCINOGENIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL NUCLEUS; CELL TRANSFORMATION, NEOPLASTIC; COLITIS; COLONIC NEOPLASMS; CYTOPLASM; DIETARY SUPPLEMENTS; DISEASE MODELS, ANIMAL; ENTEROCYTES; FRUIT; GALECTIN 3; HUMANS; MALE; MALUS; MICE; MICE, INBRED ICR; NEOPLASM PROTEINS; POLYSACCHARIDES; RANDOM ALLOCATION;

MALUS X DOMESTICA; MUS;

EID: 84859739358     PISSN: 14366207     EISSN: 14366215     Source Type: Journal    
DOI: 10.1007/s00394-011-0194-3     Document Type: Article

References (69)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ (2009) Cancer statistics, 2009. CA Cancer J Clin 59:225-249
2. Ballkwill F, Mantovani A (2001) Inflammation and cancer: back to Virchow? Lancet 357:539-545 (Pubitemid 32173595)
3. Itzkowitz SH, Yio X (2004) Inflammation and cancer IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation. Am J Physiol Gastrointest Liver Physiol 287:G7-G17 (Pubitemid 38802113)
4. Munkholm P (2003) The incidence and prevalence of colorectal cancer in inflammatory bowel disease. Aliment Pharmacol Ther 18(Suppl 2):1-5 (Pubitemid 37174709)
5. Baron JA, Cole BF, Sandler RS, Haile RW, Ahnen D, Bresalier R et al (2003) A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 348:891-899 (Pubitemid 36297997)
6. Arber N, Eagle CJ, Spicak J, Rácz I, Dite P, Hajer J et al (2006) Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med 355:885-895 (Pubitemid 44315981)
7. Joshi GP, Gertler R, Fricker R (2007) Cardiovascular thromboembolic adverse effects associated with cyclooxygenase-2 selective inhibitors and nonselective antiinflammatory drugs. Anesth Analg 105:1793-1804 (Pubitemid 350190581)
8. Solomon SD, McMurray JJ, Pfeffer MA et al (2005) Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 352:1071-1080 (Pubitemid 40365348)
9. Basterfield L, Reul JM, Mathers JC (2005) Impact of physical activity on intestinal cancer development in mice. J Nutr 135(12 Suppl):3002S-3008S (Pubitemid 43156579)
10. Papapolychroniadis C (2004) Environmental and other risk factors for colorectal cancinogenesis. Tech Coloproctol 8:S7-S9 (Pubitemid 40394499)
11. Austin GL, Adair LS, Galanko JA, Martin CF, Satia JA, Sandler RS (2007) A diet high in fruits and low in meats reduces the risk of colorectal adenomas. J Nutr 137:999-1004 (Pubitemid 46596900)
12. Hayashi A, Gillen AC, Lott JR (2000) Effects of daily oral administration of quercetin chalcone and modified citrus pectin on implanted colon-25 tumor growth in Balb-c mice. Altern Med Rev 5:546-552 (Pubitemid 32104065)
13. Nangia-Makker P, Hogan V, Honjo Y, Baccarini S, Tait L, Bresalier R et al (2002) Inhibition of human cancer cell growth and metastasis in nude mice by oral intake of modified citrus pectin. J Natl Cancer Inst 94:1854-1862 (Pubitemid 36104630)
14. Pienta KJ, Naik H, Akhtar A, Yamazaki K, Replogle TS, Lehr J et al (1995) Inhibition of spontaneous metastasis in a rat prostate cancer model by oral administration of modified citrus pectin. J Natl Cancer Inst 87:348-353
15. Rabinovich GA, Baum LG, Tinari N, Paganelli R, Natoli C, Liu FT et al (2002) Galectins and their ligands: amplifiers, silencers or tuners of the inflammatory response? Trends Immunol 23:313-320 (Pubitemid 34628775)
16. Perillo L, Marcus ME, Baum LG (1998) Galectins: versatile modulators of cell adhesion, cell proliferation, and cell death. J Mol Med 76:402-412 (Pubitemid 28218642)
17. Califice S, Castronovo V, Bracke M, van den Brule F (2004) Dual activities of galectin-3 in human prostate cancer: tumor suppression of nuclear galectin-3 vs. tumor promotion of cytoplasmic galectin-3. Oncogene 23:7527-7536 (Pubitemid 39389694)
18. Shimura T, Takenaka Y, Tsutsumi S, Hogan V, Kikuchi A, Raz A (2004) Galectin-3, a novel binding partner of beta-catenin. Cancer Res 64:636-637
19. Sacchettini JC, Baum LG, Brewer CF (2001) Multivalent proteincarbohydrate interactions. A new paradigm for supermolecular assembly and signal transduction. Biochemistry 40:3009-3015 (Pubitemid 32205344)
20. Gong HC, Honjo Y, Nangia-Makker P, Hogan V, Mazurak N, Bresalier RS et al (1999) The NH2 terminus of galectin-3 governs cellular compartmentalization and functions in cancer cells. Cancer Res 59:6239-6245 (Pubitemid 30035648)
21. Rubinstein N, Ilarregui JM, Toscano MA (2004) The role of galectins in the initiation, amplification and resolution of the inflammatory response. Tissue Antigens 64:1-12 (Pubitemid 38850363)
22. Liu FT, Hsu DK (2007) The role of galectin-3 in promotion of the inflammatory response. Drug News Perspect 20:455-460 (Pubitemid 350232814)
23. Song YK, Billiar TR, Lee YJ (2002) Role of galectin-3 in breast cancer metastasis: involvement of nitric oxide. Am J Pathol 160:1069-1075 (Pubitemid 34224593)
24. Honjo Y, Nangia-Makker P, Inohara H, Raz A (2001) Downregulation of galectin-3 suppresses tumorigenicity of human breast carcinoma cells. Clin Cancer Res 7:661-668 (Pubitemid 32707992)
25. Bresalier RS, Mazurek N, Sternberg LR, Byrd JC, Yunker CK, Nangia-Makker P et al (1998) Metastasis of human colon cancer is altered by modifying expression of the beta-galactoside-binding protein galectin-3. Gastroenterology 115:287-296 (Pubitemid 28363421)
26. Matarrese P, Tinarr N, Semeraro ML, Natoli C, Lacobelli S, Malorni W (2000) Galectin-3 overexpression protects from cell damage and death by influencing mitochondrial homeostasis. FEBS Lett 473:311-315 (Pubitemid 30249145)
27. Moon MK, Lee YJ, Battle P, Jessup JM, Raz V, Kim H R C (2001) Galectin-3 protects human breast cancinoma cells against nitric oxide-induced apoptosis, implication of galectin function during metastasis. Am J Pathol 159:1055-1060 (Pubitemid 32847195)
28. Endo K, Kohnoe S, Tsujita E, Watanabe A, Nakashima H, Baba H et al (2005) Galectin-3 expression is a potent prognostic marker in colorectal cancer. Anticancer Res 25:3117-3121
29. Tsuboi K, Shimura T, Masuda N, Ide M, Tsutsumi S, Yamaguchi S, Asao T, Kuwano H (2007) Galectin-3 expression in colorectal cancer: relation to invasion and metastasis. Anticancer Res 27:2289-2296 (Pubitemid 47228066)
30. Baldus SE, Zirbes TK, Weingarten M, Fromm S, Glossmann J, Hanisch F-G et al (2000) Increased galectin-3 expression in gastric cancer: correlations with histopathological subtypes, galactosylated antigens and tumor cell proliferation. Tumor Biol 21:258-266 (Pubitemid 30666030)
31. Hsu DK, Dowling CA, Jeng KC, Chen JT, Yang RY, Liu FT (1999) Galectin-3 expression is induced in cirrhotic liver and hepatocellular carcinoma. Int J Cancer 81:519-526 (Pubitemid 29203046)
32. van den Brule FA, Buicu C, Berchuck A, Bast RC, Deprez M, Liu FT et al (1996) Expression of the 67-kD laminin receptor, galectin-1, and galectin-3 in advanced human uterine adenocarcinoma. Hum Pathol 27:1185-1191 (Pubitemid 26374939)
33. Gillenwater A, Xu X-C, El-Naggar AK, Clayman GL, Lotan R (1996) Expression of galectins in head and neck squamous cell carcinoma. Head Neck 18:422-432 (Pubitemid 26268841)
34. Inohara H, Honjo Y, Yoshii T, Akahani S, Yoshida J, Hattori K et al (1999) Expression of galectin-3 in fine needle aspirates as a differential diagnostic marker between benign and malignant thyroid neoplasms. Cancer (Phila) 85:2475-2484 (Pubitemid 29244859)
35. Honjo Y, Inohara H, Akahani S, Yoshii T, Takenaka Y, Yoshida JI et al (2000) Expression of cytoplasmic galectin-3 as a prognostic marker in tongue carcinoma. Clin Cancer Res 6:4635-4640 (Pubitemid 32110398)
36. Prieto VG, Mourad-Zeidan AA, Melnikova V, Johnson MM, Lopez A, Diwan AH et al (2006) Galectin-3 expression is associated with tumor progression and pattern of sun exposure in melanoma. Clin Cancer Res 12:6709-6715 (Pubitemid 44876839)
37. Lotz MM, Andrews CW Jr, Korzelius CA, Lee EC, Steele GD Jr, Clarke A et al (1993) Decreased expression of Mac-2 (carbohydrate binding protein 35) and loss of its nuclear localization are associated with the neoplastic progression of colon carcinoma. Proc Natl Acad Sci USA 90:3466-3470 (Pubitemid 23111387)
38. Castronovo V, Van Den Brule FA, Jackers P, Clausse N, Liu FT, Gille C et al (1996) Decreased expression of galectin-3 is associated with progression of human breast cancer. J Pathol 179:43-48 (Pubitemid 26182865)
39. Merseburger AS, Kramer MW, Hennenlotter J, Simon P, Knapp J, Hartmann JT, Stenzl A et al (2007) Involvement of decreased galectin-3 expression in the pathogenesis and progression of prostate cancer. Prostate 68:72-77
40. Francois C, van Velthoven R, De Lathouwe O, Moreno C, Peltier A, Kaltner H et al (1999) Galectin-1 and galectin-3 binding pattern expression in renal cell carcinomas. Am J Clin Pathol 112:194-203 (Pubitemid 30212535)
41. Piantelli M, Lacobelli S, Almadori G, Lezzi M, Tinari N, Natoli C et al (2002) Lack of expression of galectin-3 is associated with a poor outcome in node-negative patients with laryngeal squamous-cell carcinoma. J Clin Oncol 20:3850-3856
42. Nakahara S, Oka N, Raz A (2005) On the role of galectin-3 in cancer apoptosis. Apoptosis 10:267-275 (Pubitemid 40603482)
43. Jedrychowski W, Maugeri U (2009) An apple a day may hold colorectal cancer at bay: recent evidence from a case-control study. Rev Environ Health 24:59-74
44. Jedrychowski W, Maugeri U, Popiela T, Kulig J, Sochacka-Tatara E, Pac A et al (2010) Case-control study on beneficial effect of regular consumption of apples on colorectal cancer risk in a population with relatively low intake of fruits and vegetables. Eur J Cancer Prev 19:42-47
45. Gerhauser C (2008) Cancer chemopreventive potential of apples, apple juice, and apple components. Planta Med 74:1608-1624
46. Kern M, Pahlke G, Balavenkatraman KK, Böhmer FD, Marko D (2007) Apple polyphenols affect protein kinase C activity and the onset of apoptosis in human colon carcinoma cells. J Agric Food Chem 55:4999-5006 (Pubitemid 47056048)
47. Veeriah S, Kautenburger T, Habermann N, Sauer J, Dietrich H, Will F, Pool-Zobel BL (2006) Apple flavonoids inhibit growth of HT29 human colon cancer cells and modulate expression of genes involved in the biotransformation of xenobiotics. Mol Carcinog 45:164-174 (Pubitemid 43358149)
48. Barth SW, Fähndrich C, Bub A, Dietrich H, Watzl B, Will F et al (2005) Cloudy apple juice decreases DNA damage, hyperproliferation and aberrant crypt foci development in the distal colon of DMH-initiated rats. Carcinogenesis 26:1414-1421 (Pubitemid 41417884)
49. Liu L, Wang ZP, Xu CT, Pan BR, Mei QB, Long Y et al (2003) Effects of Rheum tanguticm polysaccharide on TNBS-induced colitis and CD4? T cells in rats. World J Gastroenterol 9:2284-2288 (Pubitemid 37321461)
50. Li Y, Niu Y, Wu H, Zhang B et al (2009) PC-407, a celecoxib derivative, inhibited the growth of colorectal tumor in vitro and in vivo. Cancer Sci 100:2451-2458
51. Inufusa H, Nakamura M, Adachi T, Aga M, Kurimoto M, Nakatani Y, Wakano T, Miyake M, Okuno K, Shiozaki H, Yasutomi M (2001) Role of galectin-3 in adenocarcinoma liver metastasis. Int J Oncol 19:913-919
52. Block G, Patterson B, Subar A (1992) Fruit, vegetables, and cancer prevention: a review of the epidemiological evidence. Nutr Cancer 18:1-29
53. Gossé F, Guyot S, Roussi S, Lobstein A, Fischer B, Seiler N et al (2005) Chemopreventive properties of apple procyanidins on human colon cancer-derived metastatic SW620 cells and in a rat model of colon carcinogenesis. Cancinogenesis 26:1291-1295 (Pubitemid 41417908)
54. Kim HR, Lin HM, Billiran H, Raz A (1999) Cell cycle arrest and inhibition of anoikis by galectin-3 in human breast epithelial cells. Cancer Res 59:4148-4154 (Pubitemid 29393591)
55. Hsu DK, Yang RY, Pan ZX, Yu L, Salomon DR, Fung-Leung WP et al (2000) Targeted disruption of the galectin-3 gene results in attenuated peritoneal inflammatory responses. Am J Pathol 156:1073-1083 (Pubitemid 30626965)
56. Inohara H, Akahani S, Raz A (1998) Galectin-3 in stimulates cell proliferation. Exp Cell Res 245:294-302
57. Davidson PJ, Davis MJ, Patterson RJ, Ripoche MA, Poirier F, Wang JL (2002) Shuttling of galectin-3 between the nucleus and cytoplasm. Glycobiology 12:329-337 (Pubitemid 34812051)
58. Lin HM, Pestell RG, Raz A, Kim HR (2002) Galectin-3 enhances cyclin D (1) promoter activity through SP1 and a cAMP-responsive element in human breast epithelial cells. Oncogene 21:8001-8010 (Pubitemid 35430611)
59. Yoshii T, Fukumori T, Honjo Y, Inohara H, Choi Kim HR, Raz A (2002) Galectin-3 phosphorylation is required for its anti-apoptotic function and cell cycle arrest. J Biol Chem 277:6852-6857 (Pubitemid 34953068)
60. Pozharisski KM, Likhachev AJ, Klimashevski VF, Shaposhnikov JD (1979) Experimental intestinal cancer research with special reference to human pathology. Adv Cancer Res 30:165-237
61. Mori H, Ohbayashi F, Hirono I, Shimada T, Williams GM (1984) Absence of genotoxicity of the carcinogenic sulfated polysaccharides carrageenan and dextran sulfate in mammalian DNA repair and bacterial mutagenicity assays. Nutr Cancer 6:92-97 (Pubitemid 14091021)
62. Kohno H, Suzuki R, Sugie S, Tanaka T (2005) Beta-Catenin mutations in a mouse model of inflammation-related colon carcinogenesis induced by 1, 2-dimethylhydrazine and dextran sodium sulfate. Cancer Sci 96:69-76 (Pubitemid 40425381)
63. Muller S, Schaffer T, Flogerzi B, Fleetwood A, Weimann R, Schoepfer AM, Seibold F (2006) Galectin-3 modulates T cell activity and is reduced in the inflamed intestinal epithelium in IBD. Inflamm Bowel Dis 12:588-597 (Pubitemid 43977740)
64. Gorelik E, Galili U, Raz A (2001) On the role of cell surface carbohydrates and their binding proteins (lectins) in tumor metastasis. Cancer Metastasis Rev 20:245-277 (Pubitemid 34595270)
65. Elola MT, Wolfenstein-Todel C, Troncoso MF, Vasta GR, Rabinovich GA (2007) Galectins: matricellular glycan-binding proteins linking cell adhesion, migration, and survival. Cell Mol Life Sci 64:1679-1700 (Pubitemid 47036942)
66. Liu FT, Rabinovich GA (2005) Galectins as modulators of tumour progression. Nat Rev Cancer 5:29-41 (Pubitemid 40052323)
67. Toscano MA, Ilarregui JM, Bianco GA, Campagna L, Croci DO, Salatino M, Rabinovich GA (2007) Dissecting the pathophysiologic role of endogenous lectins: glycan-binding proteins with cytokine-like activity? Cytokine Growth Factor Rev 18:57-71 (Pubitemid 46401430)
68. Tomita M, Miwa M, Ouchi S, Oda T, Aketagawa J, Goto Y, Hayashi M (2009) Nonlinear intestinal absorption of (1+3)-b-D-glucan caused by absorptive and secretory transporting system. Biol Pharm Bull 32:1295-1297
69. Jain A, Gupta Y, Jain SK (2007) Perspectives of biodegradable natural polysaccharides for site-specific drug delivery to the colon. J Pharm Pharm Sci 10:86-128 (Pubitemid 46692379)